DDrare: Database of Drug Development for Rare Diseases

Searched query = "Pyogenic arthritis", "Pyoderma gangrenosum", "Acne syndrome", "PAPA syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = APD334; Adalimumab; CICLOSPORIN; Canakinumab; Ciclosporin; Cosentyx; Cosentyx®; EU/1/14/980/002; EU/1/14/980/003; Gelatin; Gevokizumab; Gevokizumab open-label; Humira; IFX-1; Infliximab; Ixekizumab; Neoral Oral Solution; Neoral soft gelatin capsules; PREDNISOLONE; Prednisolone; Secukinumab; Secukinumab 150 mg (2 injections per dose; Stelara; USTEKINUMAB; Ustekinumab; Xilonix

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04274166 (ClinicalTrials.gov)	January 2021	12/2/2020	Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum	The Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum	Pyoderma Gangrenosum	Drug: secukinumab 150 mg (2 injections per dose	Wake Forest University Health Sciences	Novartis	Not yet recruiting	18 Years	75 Years	All	6	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04274166
(ClinicalTrials.gov)

January 2021

12/2/2020

Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum

The Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum

Pyoderma Gangrenosum

Drug: secukinumab 150 mg (2 injections per dose

Wake Forest University Health Sciences

Novartis

Not yet recruiting

18 Years

75 Years

All

Phase 2

United States